Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080776670> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W3080776670 abstract "Abstract Objective Pyrotinib, a novel oral irreversible dual pan-ErbB tyrosine kinase inhibitor (TKI), has been approved in China for the treatment of HER2-positive advanced or metastatic breast cancer. This study aimed to conduct a population pharmacokinetics (PK) analysis of pyrotinib and to evaluate the impact of certain HER2-positive breast cancer patient characteristics on pyrotinib’s PK. Method A total of 1152 samples, provided by 59 adult female patients from two phase I clinical trials, were analyzed by nonlinear mixed-effects modeling. Monte Carlo simulation was conducted to assess the impact of covariates following exposure to pyrotinib. Results The PK of pyrotinib was adequately described by a one-compartment model with first-order absorption and elimination. Patient’s age and total protein levels can affect pyrotinib’s apparent volume of distribution, and concomitant use of montmorillonite powder had significant effects on the bioavailability of pyrotinib. No PK interactions were observed between capecitabine and pyrotinib. Conclusion In this study, a population PK model of pyrotinib was developed to determine the influence of patient characteristics on the PK of pyrotinib. While patient age and total protein levels can significantly affect the apparent distribution volume of pyrotinib, the magnitude of the impact was limited, thus no dosage adjustment was recommended. Furthermore, concomitant use of montmorillonite powder for diarrhea can decrease the bioavailability of pyrotinib by 50.3%." @default.
- W3080776670 created "2020-09-01" @default.
- W3080776670 creator A5012618046 @default.
- W3080776670 creator A5057746033 @default.
- W3080776670 creator A5084944295 @default.
- W3080776670 creator A5086405756 @default.
- W3080776670 creator A5087664290 @default.
- W3080776670 date "2020-08-25" @default.
- W3080776670 modified "2023-09-26" @default.
- W3080776670 title "Population pharmacokinetic modeling of pyrotinib in patients with HER2-positive advanced or metastatic breast cancer" @default.
- W3080776670 cites W1863036392 @default.
- W3080776670 cites W1999772314 @default.
- W3080776670 cites W2009945652 @default.
- W3080776670 cites W2036678828 @default.
- W3080776670 cites W2042553471 @default.
- W3080776670 cites W2073534293 @default.
- W3080776670 cites W2216184115 @default.
- W3080776670 cites W2358142057 @default.
- W3080776670 cites W2491147657 @default.
- W3080776670 cites W2577651608 @default.
- W3080776670 cites W2613098450 @default.
- W3080776670 cites W2803302189 @default.
- W3080776670 cites W2895581671 @default.
- W3080776670 cites W2897683782 @default.
- W3080776670 cites W2899115689 @default.
- W3080776670 cites W2907907709 @default.
- W3080776670 cites W2938562767 @default.
- W3080776670 cites W2947067095 @default.
- W3080776670 cites W2969604985 @default.
- W3080776670 cites W2991656815 @default.
- W3080776670 cites W3038770224 @default.
- W3080776670 doi "https://doi.org/10.1101/2020.08.23.20179655" @default.
- W3080776670 hasPublicationYear "2020" @default.
- W3080776670 type Work @default.
- W3080776670 sameAs 3080776670 @default.
- W3080776670 citedByCount "0" @default.
- W3080776670 crossrefType "posted-content" @default.
- W3080776670 hasAuthorship W3080776670A5012618046 @default.
- W3080776670 hasAuthorship W3080776670A5057746033 @default.
- W3080776670 hasAuthorship W3080776670A5084944295 @default.
- W3080776670 hasAuthorship W3080776670A5086405756 @default.
- W3080776670 hasAuthorship W3080776670A5087664290 @default.
- W3080776670 hasBestOaLocation W30807766701 @default.
- W3080776670 hasConcept C112705442 @default.
- W3080776670 hasConcept C121608353 @default.
- W3080776670 hasConcept C126322002 @default.
- W3080776670 hasConcept C143998085 @default.
- W3080776670 hasConcept C181389837 @default.
- W3080776670 hasConcept C2777909004 @default.
- W3080776670 hasConcept C2779384505 @default.
- W3080776670 hasConcept C2908647359 @default.
- W3080776670 hasConcept C526805850 @default.
- W3080776670 hasConcept C530470458 @default.
- W3080776670 hasConcept C71924100 @default.
- W3080776670 hasConcept C98274493 @default.
- W3080776670 hasConcept C99454951 @default.
- W3080776670 hasConceptScore W3080776670C112705442 @default.
- W3080776670 hasConceptScore W3080776670C121608353 @default.
- W3080776670 hasConceptScore W3080776670C126322002 @default.
- W3080776670 hasConceptScore W3080776670C143998085 @default.
- W3080776670 hasConceptScore W3080776670C181389837 @default.
- W3080776670 hasConceptScore W3080776670C2777909004 @default.
- W3080776670 hasConceptScore W3080776670C2779384505 @default.
- W3080776670 hasConceptScore W3080776670C2908647359 @default.
- W3080776670 hasConceptScore W3080776670C526805850 @default.
- W3080776670 hasConceptScore W3080776670C530470458 @default.
- W3080776670 hasConceptScore W3080776670C71924100 @default.
- W3080776670 hasConceptScore W3080776670C98274493 @default.
- W3080776670 hasConceptScore W3080776670C99454951 @default.
- W3080776670 hasLocation W30807766701 @default.
- W3080776670 hasOpenAccess W3080776670 @default.
- W3080776670 hasPrimaryLocation W30807766701 @default.
- W3080776670 hasRelatedWork W1555144605 @default.
- W3080776670 hasRelatedWork W1970245702 @default.
- W3080776670 hasRelatedWork W1970331292 @default.
- W3080776670 hasRelatedWork W2004325424 @default.
- W3080776670 hasRelatedWork W2032257480 @default.
- W3080776670 hasRelatedWork W2080955156 @default.
- W3080776670 hasRelatedWork W2379311614 @default.
- W3080776670 hasRelatedWork W2400119402 @default.
- W3080776670 hasRelatedWork W2606334551 @default.
- W3080776670 hasRelatedWork W2776273895 @default.
- W3080776670 isParatext "false" @default.
- W3080776670 isRetracted "false" @default.
- W3080776670 magId "3080776670" @default.
- W3080776670 workType "article" @default.